CPMV — Mosaic Immunoengineering Cashflow Statement
0.000.00%
- $5.62m
- $7.10m
Annual cashflow statement for Mosaic Immunoengineering, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 May 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.06 | -3.68 | -2.38 | -1.01 | -0.922 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.075 | 1.49 | 0.046 | -0.369 | 0.08 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.028 | 1.52 | 1.64 | 0.879 | 0.601 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Cash from Operating Activities | -0.987 | -0.679 | -0.69 | -0.497 | -0.241 |
Other Investing Cash Flow Items | 0.75 | 0.028 | 0.343 | 0.433 | 0 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0.75 | 0.028 | 0.343 | 0.433 | 0 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | — | 0.525 | 0.342 | 0 | 0.2 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.237 | -0.127 | -0.005 | -0.064 | -0.041 |